Standalone Authoring Environment
No project lock
JD

Start a document

The Factory opens neutral. You are not asked to pick a project or connect to a Brain until a blueprint needs one — or until you push a finished deliverable.
▦

Start Standardised Blueprint

Recurring, quality-critical documents governed by a hard-coded blueprint and a strict four-stage workflow.

SOP · BMR · Validation Protocols →
✎

Start Open Document

Exploratory and narrative drafting on a flexible canvas, guided by house rules rather than a fixed schema.

Letter Heads · Memos · Technical Notes →
Active session drafts 2 Held in memory for this session only — nothing is written to a Factory store
Document
Mode
Current stage
BM
BMR Summary MT-2026-X01
Metformin HCl · 500,000 tablets
Standardised
Stage 2 · Confirm
DN
Dev. Deviation Note #04
Technical memo · QA audience
Open
Drafting
Recent floor deliverables Direct prints and downloads — receipts only, no stored copy
Export
Delivered
PDF
APQR_Summary_2025_v1.pdf
Printed to Synnat Plant 2 floor
2 hours ago
⊘
The Factory creates, it does not store. There is no local document warehouse, index, or version repository here. Storage, indexing and retrieval belong to The Brain — once a deliverable is exported or pushed, no local data debt remains.
Workspace / Select blueprint
Context not yet resolved
JD

Select a document blueprint

Blueprints are filtered by document taxonomy. Selecting one resolves the target Brain type and declares what the blueprint will hold you to.
◧
Deferred context resolution. No Brain connection is opened by browsing. The target Brain is resolved only when you select a blueprint, and confirmed again at delivery.
Workspace / Blueprints / BMR Summary MT-2026-X01
Standardised · BP-PLC-BMR-01
JD
✓
Gather
Guided questions
✓
Confirm
Settle assumptions
3
Assess
6 quality gates
4
Organise
Fixed skeleton

What you want to achieve

Question 3 of 8
The blueprint asks for its required inputs one at a time. Nothing is drafted and nothing is formatted at this stage — you are only supplying the schema.
FIELD 3 OF 8 · REQUIRED
Which manufacturing site and suite will execute this batch?
Used to resolve the equipment train and the site-specific sections of the skeleton.
FIELD 4 OF 8 · REQUIRED
What is the target batch size?
FIELD 5 OF 8 · REQUIRED Blocking a gate
Which analytical method reference applies?
Completeness flagged this field. Type a method reference — e.g. MET-HPLC-004 Rev 2 — to clear the shortfall.
Already gathered 2
Compound
Metformin HCl
✓
Batch number
MT-2026-X01
✓

Settle the assumptions

The blueprint pre-declares what it will assume if you say nothing. Accept an assumption and it is stamped onto the deliverable as metadata; overwrite it and your value travels instead.
✓
Storage conditions
25 °C / 60 % RH
ICH Zone IVa long-term condition, inherited from the product's registered stability protocol.
Accepted
✓
Target dissolution
> 80 % at 10 hours
Extended-release specification for the 500 mg matrix tablet.
Accepted
✓
Excipient grade
Ph. Eur. Grade HPMC
Release-controlling polymer grade, as used in the last three commercial batches.
Accepted
⛭
4 assumptions settled and stamped. They travel with the deliverable as provenance metadata and will be shown to the Gate Keepers at push.

Gathered inputs & settled metadata

This is what the gates are assessing. Nothing here has been formatted yet — formatting happens in Stage 4, and only once every gate passes.
Required schema 7 of 8
Compound
Metformin HCl
✓
Batch number
MT-2026-X01
✓
Target batch size
500,000 Tablets
✓
Site & suite
Synnat Plant 2, Suite 3B
✓
Category
QA Operational / BMR Summary
✓
Analytical method ref
MET-HPLC-004 Rev 2
✓
Attached confirmed assumptions 4 of 4
Storage
25 °C / 60 % RH
✓
Target dissolution
> 80 % at 10 hours
✓
Excipient grade
Ph. Eur. Grade HPMC
✓

Organise into the fixed skeleton

All six gates passed, so formatting is now permitted. The blueprint's skeleton is fixed — sections cannot be added, removed or reordered.
1.0
Batch Identification
Compound, batch number, category, dosage form
Filled
2.0
Manufacturing Context
Site & suite, batch size, equipment train
Filled
3.0
Analytical Control
Method reference, dissolution target, assay limits
Filled
4.0
Confirmed Assumptions
Stamped provenance for the three settled assumptions
Filled
5.0
Authorisation & Qualifications
Author role metadata carried from Gate 6
Filled
Formatted preview
Synnat Pharmaceuticals · Quality Assurance

Batch Manufacturing Record Summary

MT-2026-X01 · Metformin HCl XR 500 mg · BP-PLC-BMR-01
1.0 Batch Identification

Batch MT-2026-X01 covers 500,000 extended-release tablets of Metformin HCl 500 mg, classified under QA Operational / BMR Summary.

2.0 Manufacturing Context

Manufacture is assigned to Synnat Plant 2, Suite 3B, on the qualified extended-release granulation and compression train.

3.0 Analytical Control

Release testing follows method MET-HPLC-004 Rev 2. Dissolution is specified at greater than 80 % at 10 hours.

Session draft · nothing stored in The Factory
Workspace / Investigation Technical Note
Open · House rules
JD
Pre-authoring context Type Technical Memo Audience QA Scope Single deviation
DRAFT
1.0 Executive Background H1 SCAFFOLD

The deviation observed during compression of batch MT-2026-X01 was raised on 14 February 2026 when in-process hardness readings drifted below the lower control limit on the third sampling interval. Compression was halted within eleven minutes of the first out-of-trend reading and the affected tablets were quarantined.

2.0 Technical Assessment H1 SCAFFOLD

Analytical testing confirmed that assay and content uniformity remained within specification across all quarantined samples. Dissolution at the 10-hour point met the greater than 80 % criterion, indicating the release-controlling matrix was not compromised by the hardness excursion. Root cause remains under investigation.

Table 1.1 — In-process hardness readings, compression intervals 1–6
▤
Table placeholder — caption sits above, per house rules
◔
Image placeholder — HPLC chromatogram
Figure 1.1 — HPLC chromatogram, principal peak at RRT 1.00
3.0 Conclusion H1 SCAFFOLD

The batch meets all release criteria. The hardness excursion is attributed to a turret pre-compression setting and is addressed by the corrective action logged against the equipment record.

Workspace / BMR Summary MT-2026-X01 / Delivery
The Factory seam
JD

Deliver this document

This drawer is the only connection The Factory has to The Brain. Take the document to the floor, or propose it into a Brain — either way, nothing stays here.
DOCX
BMR_Summary_MT-2026-X01.docx
Standardised · BP-PLC-BMR-01 5 sections 6/6 gates passed
Ready
A

Direct print or download

Local floor execution — the file goes to you, not to a store
⊘
Zero local storage. The Factory writes no copy, no index entry and no version record. What appears on the workspace afterwards is a receipt, not a file.
B

Push to a Central Brain

Proposed into the Gate Keeper queue under per-Brain isolation
Target Brain
Metformin XR 500
Brain type
Product Life Cycle
⚿ Read-only · resolved by blueprint
Destination data set
Attached provenance
⛭
3 confirmed assumptions settled and stamped. Storage 25 °C / 60 % RH · Dissolution > 80 % at 10 h · Excipient Ph. Eur. Grade HPMC
Rationale for the Gate Keepers
Assigned Gate Keepers
AR
Anita Rao
anita.rao@example.com
QA Custodian
MS
Meera Shah
meera.shah@example.com
AD Lead
Proposal submitted
JD
✓

Proposal is with the Gate Keepers

The document has left The Factory. Anita Rao and Meera Shah will review it in the Metformin XR 500 Brain.
Document
BMR_Summary_MT-2026-X01.docx
Target Brain
Metformin XR 500 · Product Life Cycle
Destination data set
Batch Records (BMR)
Gates
6 of 6 passed
Assumptions stamped
4
Queue position
2nd · typical review 1–2 days
⊘
Nothing remains in The Factory. The session draft, the parsed schema and the generated file have all been released. Retrieval from here on is a Brain operation.
✓Done